Results 91 to 100 of about 54,372 (282)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Tapasin gene polymorphism in systemic onset juvenile rheumatoid arthritis: a family-based case-control study

, 2005
Juvenile rheumatoid arthritis (JRA) comprises a group of chronic systemic inflammatory disorders that primarily affect joints and can cause long-term disability.
Woo, P, Colbert, RA, Bukulmez, H, Thompson, SD, Twine, NA, Tsoras, M, Glass, DN, Olson, JM, Fife, M, Elston, RC   +9 more
core  

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, EarlyView.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source

Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide

São Paulo Medical Journal
CONTEXT: Patients with refractory juvenile idiopathic arthritis can benefit from aggressive therapy. CASE REPORT: We followed the clinical course of 4 patients (2 male, 2 female) aged 9.1-17.8 years (mean of 14.5 years) with polyarticular onset of ...
Tania Caroline Monteiro de Castro, Maria Teresa Terreri, Claudio Len, Maria Odete Esteves Hilário   +3 more
doaj   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease

Internal Medicine Journal, EarlyView.
Abstract Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin‐6 (IL‐6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi‐organ failure.
Dipti Talaulikar, Jun Yen Ng, Adam Bryant, Annmarie Bosco, Hugh C. Caterson, Pratyush Giri, Pravin Hissaria, Simon J. Harrison, Stephen Lade, Connull Leslie, Jacinta Perram, H. Miles Prince, Dejan Radeski, Maureen Rischmueller, Craig Wallington‐Gates, Nicholas Weber, Alberta Hoi   +16 more
wiley   +1 more source

Biologic treatments in rheumatoid arthritis and juvenile idiopathic arthritis [PDF]

, 2006
A number of biological approaches to the management of inflammtory arthropathies have been explored. These include the development of IL-1 receptor antagonists and TNF antagonists. Four biological agents are currently marketed in Europe.
Borg, Andrew A.
core  

Juvenile idiopathic arthritis morbidity rate in rural and urban areas of Poland 2008–2012 [PDF]

, 2015
[b][/b][b]Objective. [/b]The aim of this study was to investigate the juvenile idiopathic arthritis (JIA) morbidity rate in the Polish population, calculated per 1,000 inhabitants of a given province, taking into account the differences between urban and
Andrzej Śliwczyński, Melania Brzozowska, Iltchev, P., Sierocka, A., Tlustochowicz, M., Małgorzata Tłustochowicz, Sliwczynski, A., Tlustochowicz, W., Michał Marczak, Marczak, M., Witold Tłustochowicz, Aleksandra Sierocka, Brzozowska, M., Petre Iltchev   +13 more
core   +1 more source

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra, Cecile Wasielewski, Bruno Špiljak, Maja Sabalić‐Schoener, Sebastien Jungo, Ivan Alajbeg   +5 more
wiley   +1 more source

CLINICAL BLOOD IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN KRASNOYARSK REGION

Siberian Journal of Life Sciences and Agriculture, 2019
The aim of the study – assessment of the features of clinical blood in patients with juvenile idiopathic arthritis. It showed an increase in the absolute number of lymphocytes and monocytes, platelets, neutrophils, increased erythrocyte sedimentation ...
Julia Semenovna Akopova, Olga Mikhailovna Miller, Semenovna Irena Akopova   +2 more
doaj   +1 more source